Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Reports from P. Kiewe and colleagues advance knowledge in breast cancer
December 25th, 2008
"Ertumaxomab is an intact bispecific antibody targeting HER2/neu and CD3 with preferential binding to activating Fc gamma type I/III-receptors, resulting in the formation of a tri-cell complex among tumour cell, T cell and accessory cell," investigators in Berlin, Germany report. "Recently, the antibody demonstrated antitumour efficacy against HER2/neu low-expressing tumours resistant to trastuzumab. Data from a completed Phase I study in metastatic breast cancer patients indicates strong immune responses," wrote P. Kiewe and colleagues. The researchers concluded: "Owing to efficient tumour cell destruction by humoral and T-cell-dependent mechanisms,...
Source: Women's Health Weekly (2008-12-25)
|
